Excellent
Fully Aligned
Patient Risk:
Low
Summary
AI response claims are fully consistent with the supplied label excerpts for nilotinib/Tasigna regarding QT prolongation, torsade de pointes/sudden death risks, contraindications, monitoring, food restriction, and relevant drug interaction avoidance; no contradictions, unsupported claims, or material omissions within the stated QT/sudden-death scope.
Category Scores
Accurate Statements
Nilotinib/Tasigna prolongs the QT interval and torsade de pointes may result in syncope, seizure, and/or death; ECG monitoring and electrolyte monitoring are described.
0 BOXED WARNING; 5.2 QT Prolongation; 5.12 Monitoring Laboratory Tests
Sudden deaths have been reported in patients receiving Tasigna and avoidance guidance is tied to QT-risk states.
0 BOXED WARNING; 5.3 Sudden Deaths
Tasigna is contraindicated in patients with hypokalemia, hypomagnesemia, or long QT syndrome.
4 CONTRAINDICATIONS; 0 BOXED WARNING
Food intake must be avoided around dosing (empty stomach dosing window: no food at least 2 hours before and at least 1 hour after).
2.1 Recommended Dosage (food restriction / empty stomach)
Coadministration with strong CYP3A4 inhibitors, QT-prolonging agents, and food that increases exposure should be avoided due to risk of significant QT prolongation.
0 BOXED WARNING; 5.2 QT Prolongation; 7.2 Drugs That Prolong the QT Interval
Monitoring includes ECGs at baseline, 7 days after initiation, and periodically thereafter, including after dose adjustments, and monitoring/correcting electrolytes (including calcium and magnesium).
0 BOXED WARNING; 5.2 QT Prolongation; 5.12 Monitoring Laboratory Tests; 2.4 Dosage Modification for QT Interval Prolongation
Dosage modification actions include withholding Tasigna, correcting potassium/magnesium, resuming based on QTc thresholds, and repeating ECG about 7 days after dose adjustment.
2.4 Dosage Modification for QT Interval Prolongation
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
No label-discordant claims or material omissions were made within the QT prolongation/sudden death scope provided.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement